BioSpace News Archive

Ubiquitous potential, possible safety advantages and the recent growth of cell and gene therapy are driving investment in a different type of genetic editing.

Valneva SE, a specialty vaccine company, announced it will present on its single-shot chikungunya vaccine, IXCHIQ®, moderate a roundtable on the Zika and chikungunya viruses, and participate in a panel discussion on efforts to eradicate chikungunya at the 24th World Vaccine Congress, which will take place between April 1-4, 2024 at the Walter E.

Hansa Biopharma AB announced the publication of its 2023 Annual and Sustainability Reports.

Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, published “Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor” as poster presentation from March 12 to 15, 2024 at the 14th World ADC London.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the publication of the March 2024 Letter to Shareholders.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, reported its financial results for the fiscal year ended December 31, 2023 and provided a business update.

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors. Both bring extensive careers in the strategic, financial and corporate development aspects of building leading biotechnology companies.

SEQSTER PDM Inc., the leading patient-centric healthcare technology company, has been selected by the Multiple Sclerosis Association of America for its patient-centricity, 1-Click Records™ and cutting-edge longitudinal health record.

Rockwell Medical, Inc. announced financial and operational results for the three months and twelve months ended December 31, 2023.

BD, a leading global medical technology company, issued the following statement regarding the March 19, 2024 U.S. Food and Drug Administration Safety Communication, which provided important updates on FDA’s ongoing evaluation of certain plastic syringes.